SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is trending as traders speculate on a potential breakout, with the community actively debating whether current institutional accumulation and technical indicators signal an imminent move toward double digits or if the stock remains stuck in a consolidation range. Retail investors are split between holding for long-term growth driven by fundamental metrics and reacting to frequent short-term price volatility.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing significant market attention and speculative volume as investors debate the potential for a buyout or strategic shift following unusual trading patterns. The community remains deeply divided, with many long-term holders expressing frustration over persistent price suppression while others speculate that recent regulatory updates and heavy institutional volume signal a looming re-rating for the stock.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Digital is experiencing significant price volatility as institutional investors aggressively trade the stock amid sector-wide rotation and uncertainty regarding hyperscaler AI capacity utilization. Community sentiment is deeply divided, with some investors viewing the pullback as a prime accumulation opportunity based on the company's secured power portfolio, while others remain cautious due to broader market de-risking and speculation regarding potential supply imbalances in the AI infrastructure space.

LightPath Technologies, Inc. engages in the design, development, manufacture, and distribution of optical and infrared components. Its products include molded glass and assemblies, infrared molded lenses, diamond turned, conventional ground and polished ground lenses and assemblies, and collimator assemblies, which are used in applications involving light detection and ranging technology. The firm supports a range of customers in the field of industrial, laser, defense, medical, telecommunications, and instrumentation. The company was founded in1985 and is headquartered in Orlando, FL.

Lightpath Technologies, Inc. - Ordinary Shares - Class A

LightPath Technologies is trending as investors capitalize on the company's strategic positioning within the defense and drone supply chain, particularly amid rising demand for domestic critical material alternatives like BlackDiamond glass. The community is actively discussing potential growth catalysts, including government-backed defense contract opportunities and the company's role as an enabling technology provider in the burgeoning counter-UAS market.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is seeing significant investor attention following a regulatory filing confirming that Nvidia holds a 9.3% stake in the company. The market is actively debating this catalyst, with many investors interpreting the move as a major vote of confidence in the firm's AI infrastructure and GPU-backed business model despite recent volatility.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce is trending as the market reacts to a flurry of new commercial engine agreements with Philippine Airlines and Somon Air, alongside significant progress in its SMR and GCAP defense initiatives. The community remains highly focused on the company's strong industrial momentum, potential narrow-body market re-entry, and anticipation of upcoming mid-year financial results as catalysts for further growth.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is trending as investors debate whether the current price represents a generational buying opportunity or a signal of fundamental weakness amid intense competition in the energy drink sector. The community is sharply divided, with many aggressively averaging down while waiting for the upcoming quarterly earnings report to spark a potential short squeeze.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicor Corp. is facing significant volatility following its latest earnings report, with community sentiment divided between investors concerned by a sharp decline in backlog and those betting on a long-term turnaround fueled by proprietary vertical power delivery technology for AI data centers. While some market participants express frustration over management's outlook and potential delays, others are using the pullback to accumulate shares, viewing the company as a critical, undervalued play on the infrastructure required to power next-generation AI hardware.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The QQQ is trending as investors grapple with conflicting signals from escalating geopolitical tensions, rising energy costs, and fresh tariff threats that are clashing with a persistent AI-driven momentum. The community remains deeply polarized, with active debates centered on whether current price levels are an overextended bull trap or a resilient rally fueled by institutional backing.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as high trading volume and significant institutional accumulation spark intense debate over its pivot to agentic AI orchestration and the potential for a short squeeze. While bulls are encouraged by GAAP profitability and aggressive share buybacks, the community remains divided over the stock's persistent price stagnation and the role of high short interest in its recent volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tuesday Sector Leaders: Drugs, Gas Utilities

In trading on Tuesday, drugs shares were relative leaders, up on the day by about 2%. Leading the group were shares of Crinetics Pharmaceuticals, up about 98.8% and shares of Pyxis Oncology up about 18.7% on the day.

Also showing relative strength are gas utilities shares, up...

Short Interest in Pyxis Oncology, Inc. (NASDAQ:PYXS) Drops By 14.7%

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) saw a significant drop in short interest in the month of April. As of April 15th, there was short interest totaling 2,269,065 shares, a drop of 14.7% from the March 31st total of 2,660,931 shares. Approximately 4.0% of the company's stock are...

Pyxis Oncology (NASDAQ:PYXS) Upgraded by Wall Street Zen to "Hold" Rating

Wall Street Zen upgraded shares of Pyxis Oncology from a "sell" rating to a "hold" rating in a research report on Monday...

Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold ratin...

Wall Street Zen Downgrades Pyxis Oncology (NASDAQ:PYXS) to Sell

Wall Street Zen lowered Pyxis Oncology from a "hold" rating to a "sell" rating in a report on Sunday...

Pyxis Oncology (NASDAQ:PYXS) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded Pyxis Oncology from a "sell" rating to a "hold" rating in a research note on Saturday...

Rachel Humphrey Sells 13,896 Shares of Pyxis Oncology (NASDAQ:PYXS) Stock

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) Director Rachel Humphrey sold 13,896 shares of the stock in a transaction on Monday, April 21st. The shares were sold at an average price of...

Q1 EPS Estimates for Pyxis Oncology Raised by HC Wainwright

Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Analysts at HC Wainwright lifted their Q1 2026 earnings per share (EPS) estimates for shares of Pyxis Oncology in a report issued on Tuesday, March...

Pyxis Oncology (NASDAQ:PYXS) Director Rachel Humphrey Sells 13,896 Shares

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) Director Rachel Humphrey sold 13,896 shares of the business's stock in a transaction dated Monday, April 21st. The shares were sold at an average...

FY2029 EPS Estimates for Pyxis Oncology Lifted by Analyst

Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Analysts at HC Wainwright upped their FY2029 earnings per share estimates for shares of Pyxis Oncology in a research report issued on Tuesday, March...

Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The company was founded by David Steinberg, Shaan C. Gandhi, and John L. Flavin on June 11, 2018 and is headquartered in Boston, MA.

Pyxis Oncology Inc

Bearish Sentiment

Too early to tell

Neocloud stocks, including $NBIS and $CRWV, have been under significant selling pressure in recent weeks. Is the selloff finally over? Cast your vote and drop your reasoning in the comments.

Is the pullback in neocloud stocks over?  
 
Explain your reasoning in the comments.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.34	--	--	N/A
Q1 '26	-$0.36	-$0.37	-1.53%	MISSED
Q4 '25	-$0.34	-$0.28	18.70%	BEAT
Q3 '25	-$0.33	-$0.35	-4.80%	MISSED
Q2 '25	-$0.35	-$0.30	14.69%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

PYXSPyxis Oncology Inc

Upcoming Earnings: Q2 '26

Historical Earnings

Latest PYXS News